Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Maine: - Harold Alfond Center for Cancer Care — Augusta, Maine
- Eastern Maine Medical Center — Bangor, Maine
- MaineHealth Waldo Hospital — Belfast, Maine
- MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
- Lafayette Family Cancer Center-EMMC — Brewer, Maine
Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Maine: - Harold Alfond Center for Cancer Care — Augusta, Maine
- Eastern Maine Medical Center — Bangor, Maine
- MaineHealth Waldo Hospital — Belfast, Maine
- MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
- Lafayette Family Cancer Center-EMMC — Brewer, Maine
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Maine: - MaineHealth Maine Medical Center - Portland — Portland, Maine
- MaineHealth Cancer Care Center of York County — Sanford, Maine
- MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine
- MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Maine: - MaineHealth Coastal Cancer Treatment Center — Bath, Maine
- MaineHealth Maine Medical Center - Portland — Portland, Maine
- MaineHealth Cancer Care Center of York County — Sanford, Maine
- MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine
- MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Maine: - Lafayette Family Cancer Center-EMMC — Brewer, Maine
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Maine: - MaineHealth Maine Medical Center - Portland — Portland, Maine
- MaineHealth Cancer Care Center of York County — Sanford, Maine
- MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Maine: - Eastern Maine Medical Center — Bangor, Maine
- Maine Children's Cancer Program — Scarborough, Maine
Phase 3 Recruiting Industry
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in Maine: - New England Cancer Specialists ( Site 0095) — Westbrook, Maine
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Maine: - Local Institution - 0127 — Scarborough, Maine
Phase 3 Recruiting Industry
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Maine: - New England Cancer Specialists ( Site 0139) — Westbrook, Maine
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Maine: - Lafayette Family Cancer Center-EMMC — Brewer, Maine
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Maine: - Lafayette Family Cancer Center-EMMC — Brewer, Maine
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Maine: - Lafayette Family Cancer Center-EMMC — Brewer, Maine
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Maine: - MaineHealth Coastal Cancer Treatment Center — Bath, Maine
- MaineHealth Cancer Care and IV Therapy - Brunswick — Brunswick, Maine
- MaineHealth Maine Medical Center - Portland — Portland, Maine
- MaineHealth Cancer Care Center of York County — Sanford, Maine
- MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Maine: - Harold Alfond Center for Cancer Care — Augusta, Maine
- MaineHealth Waldo Hospital — Belfast, Maine
- MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
- MaineHealth Cancer Care and IV Therapy - Brunswick — Brunswick, Maine
- Mid Coast Hospital — Brunswick, Maine
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Maine: - Massive Bio SYNERGY-AI site — Scarborough, Maine
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Maine: - Central Maine Medical Center — Lewiston, Maine